Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lercanidipine is a long-acting dihydropyridine calcium channel blocker used primarily for the treatment of hypertension (high blood pressure). It works by inhibiting the influx of calcium ions through voltage-gated L-type calcium channels in vascular smooth muscle cells. This action leads to relaxation and dilation of blood vessels (vasodilation), thereby lowering peripheral resistance and reducing blood pressure. Compared to older dihydropyridine agents like nifedipine or amlodipine it has a slower onset and longer duration of action with potentially fewer adverse effects such as peripheral edema. It is not approved in the United States but is widely marketed internationally under various brand names[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lercanidipine.